title: Anti-Inflammatory Therapy Modulates Nrf2-Keap1 in Kidney from Rats with Diabetes.
abstract: This study addressed the relationship of proinflammatory cytokines and Nrf2-Keap1 system in diabetic nephropathy. The experimental groups were control, diabetic, and diabetic treated with mycophenolate mofetil (MMF). The renal function, proinflammatory and profibrotic cytokines, oxidative stress, morphology, and nephrin expression were assessed. Diabetic group showed impaired renal function in association with oxidative stress and decreased Nrf2 nuclear translocation. These results were associated with increased mesangial matrix index, interstitial fibrosis, and increased nephrin expression in cortex and urine excretion. Additionally, interleukin-1β, IL-6, and transforming growth factor-β1 were increased in plasma and kidney. MMF treatment conserved renal function, prevented renal structural alterations, and partially prevented the proinflammatory and profibrotic cytokines overexpression. Despite that MMF treatment induced nephrin overexpression in renal tissue, preventing its urinary loss. MMF salutary effects were associated with a partial prevention of oxidative stress, increased Nrf2 nuclear translocation, and conservation of antioxidant enzymes in renal tissue. In conclusion, our results confirm that inflammation is a key factor in the progression of diabetic nephropathy and suggest that treatment with MMF protects the kidney by an antioxidant mechanism, possibly regulated at least in part by the Nrf2/Keap1 system, in addition to its well-known anti-inflammatory effects.
authors.affiliation: Laboratory of Renal Physiopathology, Juan Badiano 1, 14080 Mexico City, DF, Mexico; Department of Nephrology, Instituto Nacional de Cardiología-Ignacio Chávez, Juan Badiano 1, 14080 Mexico City, DF, Mexico.
authors.forename: Abraham Said
authors.initials: AS
authors.lastname: Arellano-Buendía
authors.affiliation: Laboratory of Renal Physiopathology, Juan Badiano 1, 14080 Mexico City, DF, Mexico; Department of Nephrology, Instituto Nacional de Cardiología-Ignacio Chávez, Juan Badiano 1, 14080 Mexico City, DF, Mexico.
authors.forename: Montserrat
authors.initials: M
authors.lastname: Tostado-González
authors.affiliation: Laboratory of Renal Physiopathology, Juan Badiano 1, 14080 Mexico City, DF, Mexico; Department of Nephrology, Instituto Nacional de Cardiología-Ignacio Chávez, Juan Badiano 1, 14080 Mexico City, DF, Mexico.
authors.forename: Fernando Enrique
authors.initials: FE
authors.lastname: García-Arroyo
authors.affiliation: Laboratory of Renal Physiopathology, Juan Badiano 1, 14080 Mexico City, DF, Mexico; Department of Nephrology, Instituto Nacional de Cardiología-Ignacio Chávez, Juan Badiano 1, 14080 Mexico City, DF, Mexico.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Cristóbal-García
authors.affiliation: Histopathology Laboratory, Research Subdivision, School of Medicine, Universidad Panamericana, Donatello 43, 03910 Mexico City, DF, Mexico.
authors.forename: María Lilia
authors.initials: ML
authors.lastname: Loredo-Mendoza
authors.affiliation: Laboratory of Renal Physiopathology, Juan Badiano 1, 14080 Mexico City, DF, Mexico; Department of Nephrology, Instituto Nacional de Cardiología-Ignacio Chávez, Juan Badiano 1, 14080 Mexico City, DF, Mexico.
authors.forename: Edilia
authors.initials: E
authors.lastname: Tapia
authors.affiliation: Laboratory of Renal Physiopathology, Juan Badiano 1, 14080 Mexico City, DF, Mexico; Department of Nephrology, Instituto Nacional de Cardiología-Ignacio Chávez, Juan Badiano 1, 14080 Mexico City, DF, Mexico.
authors.forename: Laura-Gabriela
authors.initials: LG
authors.lastname: Sánchez-Lozada
authors.affiliation: Laboratory of Renal Physiopathology, Juan Badiano 1, 14080 Mexico City, DF, Mexico; Department of Nephrology, Instituto Nacional de Cardiología-Ignacio Chávez, Juan Badiano 1, 14080 Mexico City, DF, Mexico.
authors.forename: Horacio
authors.initials: H
authors.lastname: Osorio-Alonso
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000378:metabolism / Q000517:prevention & control; D018836:Inflammation Mediators / Q000378:metabolism; D000072019:Kelch-Like ECH-Associated Protein 1 / Q000378:metabolism*; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009173:Mycophenolic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D051267:NF-E2-Related Factor 2 / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000893:Anti-Inflammatory Agents; D018836:Inflammation Mediators; C486610:KEAP1 protein, rat; D000072019:Kelch-Like ECH-Associated Protein 1; D051267:NF-E2-Related Factor 2; C495637:Nfe2l2 protein, rat; D009173:Mycophenolic Acid